MX2022015656A - Formulaciones oftalmaticas topicas de liposomas cargados con acetonido de triamcinolona como terapia primaria para el edema macular secundario a la oclusion de la vena retiniana de rama. - Google Patents

Formulaciones oftalmaticas topicas de liposomas cargados con acetonido de triamcinolona como terapia primaria para el edema macular secundario a la oclusion de la vena retiniana de rama.

Info

Publication number
MX2022015656A
MX2022015656A MX2022015656A MX2022015656A MX2022015656A MX 2022015656 A MX2022015656 A MX 2022015656A MX 2022015656 A MX2022015656 A MX 2022015656A MX 2022015656 A MX2022015656 A MX 2022015656A MX 2022015656 A MX2022015656 A MX 2022015656A
Authority
MX
Mexico
Prior art keywords
macular edema
triamcinolone acetonide
vein occlusion
topical ophthalmic
retinal vein
Prior art date
Application number
MX2022015656A
Other languages
English (en)
Inventor
Arturo Santos
Jose Navarro
Juan C Altamirano
Alejandro Gonzalez
Original Assignee
Opko Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Pharmaceuticals Llc filed Critical Opko Pharmaceuticals Llc
Publication of MX2022015656A publication Critical patent/MX2022015656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención descrita es un método para tratar pacientes que tienen edema macular secundario a la oclusión de una vena retiniana de rama. Los pacientes son tratados con una formulación de nanopartículas liposómicas que comprende liposomas termodinámicamente estables y un esteroide tal como acetónido de triamcinolona. La formulación es una formulación oftálmica tópica administrada tópicamente para tratar la enfermedad del segmento posterior.
MX2022015656A 2020-06-15 2021-05-04 Formulaciones oftalmaticas topicas de liposomas cargados con acetonido de triamcinolona como terapia primaria para el edema macular secundario a la oclusion de la vena retiniana de rama. MX2022015656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063039095P 2020-06-15 2020-06-15
PCT/US2021/030593 WO2021257193A1 (en) 2020-06-15 2021-05-04 Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion

Publications (1)

Publication Number Publication Date
MX2022015656A true MX2022015656A (es) 2023-03-22

Family

ID=76076521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015656A MX2022015656A (es) 2020-06-15 2021-05-04 Formulaciones oftalmaticas topicas de liposomas cargados con acetonido de triamcinolona como terapia primaria para el edema macular secundario a la oclusion de la vena retiniana de rama.

Country Status (5)

Country Link
US (1) US20230241080A1 (es)
EP (1) EP4164593A1 (es)
CL (1) CL2022003593A1 (es)
MX (1) MX2022015656A (es)
WO (1) WO2021257193A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
BR112015003658B1 (pt) * 2012-08-21 2022-09-27 Opko Pharmaceuticals, Llc Formulação oftálmica, uso da dita formulação no tratamento de doença oftálmica do segmento posterior, formulação de lipossomas e suspensão oftálmica lipossomal
EP3400014A1 (en) * 2016-01-08 2018-11-14 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
EP3968949A1 (en) * 2019-05-16 2022-03-23 OPKO Pharmaceuticals, LLC Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery

Also Published As

Publication number Publication date
US20230241080A1 (en) 2023-08-03
CL2022003593A1 (es) 2023-08-25
EP4164593A1 (en) 2023-04-19
WO2021257193A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
JP6209777B2 (ja) 眼の疾病及び疾患のための組成物及び治療
Jampol Pharmacologic therapy of aphakic cystoid macular edema: A review
JP2010531298A5 (es)
US4262007A (en) Method for the treatment of viral skin diseases
CN108853312A (zh) 聚桂醇外用凝胶及其制备方法
KR20060121238A (ko) 축적된 지방의 의약적 지방 분해
JP2018532806A (ja) デオキシコール酸およびその塩による蓄積脂肪の処置方法
JP2007509085A (ja) 薬物標的化された局所的脂肪分解
BR112023018896A2 (pt) Tratamento da dor em pacientes pediátricos por administração de composições anestésicas lipossômicas de liberação prolongada
JP2002520281A (ja) 粘膜疾患の局所治療における使用のためのビタミンｅおよびそのエステル
Saveljev et al. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE)
US4390539A (en) Method for the treatment of viral skin diseases
MX2022015656A (es) Formulaciones oftalmaticas topicas de liposomas cargados con acetonido de triamcinolona como terapia primaria para el edema macular secundario a la oclusion de la vena retiniana de rama.
CA2754008C (en) Medicinal cosmetic lipoatrophy
MX2022013665A (es) Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MX2023012793A (es) Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas.
EP3167881B1 (en) Locally administered ethamsylate as a medicament
AU2014284101B2 (en) Treating skin ulcers
유현정 et al. Efficacy of intravenous midazolam/fentanyl for pain relief during vascular access intervention
Aljerf et al. In Modern Ocular Pharmacology-Dexamethasone the Top Active Corticosteroid
MX2024003580A (es) Metodos de tratamiento de enfermedades inflamatorias oculares.
Malerbi et al. Hyperbaric oxygen therapy for choroidal neovascularization: A pilot study
MX2022015792A (es) Composiciones farmaceuticas topicas.
Vaghasiya et al. Topical therapy of various dermatoses with ImpoyzTM (clobetasol propionate) cream 0.025%